Other factors related to the immunogenic profile of SCC that may explain the efficacy of PD-1/PD-L1 inhibitors seen in this malignancy is its high mutation rate that probably causes expression of a large amount of tumor antigens. The gene discussed is CD274; the disease is neoplasm.